FindTrial
Sign In

CX-2009

DRUG2 trials

Sponsors

CytomX Therapeutics

Conditions

Breast CancerBreast NeoplasmsBreast Neoplasms, Hormone Receptor Positive/HER2 NegativeBreast Neoplasms, Triple-NegativeHead and Neck CancerNeoplasmsNon Small Cell Lung CancerOvarian Cancer

Phase 1

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
TerminatedNCT03149549
CytomX TherapeuticsBreast Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer +2
Start: 2017-06-01End: 2020-09-10Updated: 2024-01-05

Phase 2

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
CompletedNCT04596150
CytomX TherapeuticsBreast Cancer, Breast Neoplasms, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative +2
Start: 2020-12-29End: 2023-06-02Updated: 2024-01-23

Related Papers

Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)
Cancer Research2023-03-015 citations
Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab
Cancer Research2022-02-15
Abstract PS11-07: Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166
Cancer Research2021-02-151 citations
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
Journal of Clinical Oncology2020-05-2011 citations
Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166.
Journal of Clinical Oncology2020-05-201 citations
Abstract LB-185: Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors
Cancer Research2019-07-014 citations
Abstract 212: CD166-DM4 probody drug conjugate (CX-2009) treatment of 198 patient-derived xenograft models (PDX) in a mouse clinical trial format
Cancer Research2019-07-012 citations
Abstract LB-185: Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors
Immunology2019-07-01
Abstract 212: CD166-DM4 probody drug conjugate (CX-2009) treatment of 198 patient-derived xenograft models (PDX) in a mouse clinical trial format
Experimental and Molecular Therapeutics2019-07-01